India Court Clears Dr. Reddy's to Export Semaglutide Generics Amid Patent Dispute with Novo Nordisk

An Indian court has allowed Dr. Reddy's Laboratories to manufacture and export generic versions of Novo Nordisk's semaglutide drug, ahead of global patent expiries in 2026. The court rejected Novo Nordisk's petition to block production, but Dr. Reddy's must not sell the products in India until Novo's patent lapses. Semaglutide is the main ingredient in Novo's diabetes medicine Ozempic and weight-loss drug Wegovy. Dr. Reddy's plans to supply non-branded semaglutide to over 80 countries, joining a growing race among generics from India and China, and firms like Sandoz and Aspen.